Lantheus Holdings, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. Amounts are in millions of dollars except per-share data. Lantheus develops and markets radiopharmaceutical oncology, precision diagnostic and related products.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change / context |
|---|---|---|---|
| Revenue | $370.0 | $300.8 | Up 23.0% |
| Gross profit / margin | $241.8 / 65.4% | $77.1 / 25.6% | Higher mainly because the prior period included a $116.4 AZEDRA product intangible impairment in cost of goods sold, and from higher PYLARIFY and DEFINITY sales |
| Operating income (loss) | $106.6 | $(9.3) | 2024 included a $6.3 gain on asset sale |
| Net income (loss) | $131.1 | $(2.8) | 2024 included a $60.7 unrealized gain on the Perspective equity investment |
| Diluted EPS | $1.87 | $(0.04) | GAAP diluted EPS |
| Operating cash flow | $127.2 | $108.5 | Cash generation increased |
| Investing cash flow | $(106.5) | $(44.5) | Included Perspective share purchases and a $28.0 option payment in 2024; Cerveau asset acquisition in 2023 |
| Financing cash flow | $(16.8) | $(8.7) | Primarily share-award tax withholding |
Revenue drivers: PYLARIFY revenue was $258.9, up 32.4%; DEFINITY was $76.6, up 11.2%; and TechneLite was $21.7, up 3.5%. Precision Diagnostics revenue rose 9.0% to $104.2. Strategic partnerships and other revenue fell 27.5% to $6.5, partly reflecting the 2023 sale of the RELISTOR royalty asset. AZEDRA contributed $0.4; production ended after March 1, 2024.
Balance sheet, debt and liquidity
- Cash and cash equivalents were $718.3 at March 31, 2024, versus $713.7 at December 31, 2023. Cash, cash equivalents and restricted cash totaled $719.9.
- Accounts receivable was $337.4 and inventory was $69.8. Total assets were $1,831.3; stockholders’ equity was $945.5.
- Long-term debt principal was $575.0, consisting of 2.625% convertible notes due December 2027. The notes’ carrying value was $575.0 and estimated fair value was $636.0. No borrowings were outstanding under the $350.0 revolving facility; the company reported compliance with its covenants.
- Management said cash, expected operating cash generation and continued access to the revolver should meet requirements over the next 12 months and beyond. Access to the full revolver may be constrained by its covenants.
Material developments, outlook and risks
- Perspective investment and agreements: Lantheus invested $78.3 in Perspective shares and held 19.90% of outstanding shares (17.35% fully diluted) after the March purchase. The investment was carried at $139.0 at quarter-end. A $28.0 upfront option payment was expensed as acquired in-process research and development. The company also transferred its Somerset facility assets and lease to Perspective for $8.0, recognizing a $6.3 gain.
- Pipeline: PNT2002 met its SPLASH trial primary endpoint; interim overall-survival data remained immature. Lantheus expected the analysis at 75% of target events in Q3 2024. PNT2003’s ANDA was accepted for filing, but Novartis entities sued for patent infringement. A Hatch-Waxman stay could delay approval; the company said a full 30-month stay followed by successful approval could mean a 2026 launch.
- Product and reimbursement risks: PYLARIFY faces growing competition. Its Medicare hospital outpatient transitional pass-through payment status could expire December 31, 2024; future reimbursement arrangements may affect adoption. Mo-99 supply and third-party manufacturing and distribution disruptions could also affect sales.
- Other operating items: Sales and marketing, G&A and R&D expenses increased 39.6%, 105.8% and 57.3%, respectively. The increases reflected commercial investment, technology and personnel costs, and pipeline spending, including the Perspective option payment. Q1 2023 included $15.6 of AZEDRA-related R&D impairment, while Q1 2024 included the $28.0 Perspective charge.
- Legal and contingent matters: The company disclosed the PNT2003 patent litigation and stated it had no other material ongoing litigation. It reported $2.7 of fair-value contingent consideration liabilities, while potential payments associated with a prior acquisition could total approximately $85.0, subject to milestones and other conditions.
- Leadership: Brian Markison became CEO on March 1, 2024; former CEO Mary Anne Heino became Board Chair. The filing gave no numerical revenue or earnings guidance.
Most important facts for investors to verify
- How much reported earnings growth reflects underlying product performance versus the $60.7 unrealized investment gain, asset-sale gain and prior-year AZEDRA impairment comparison.
- Whether PYLARIFY and DEFINITY growth continues amid competition, and the reimbursement outcome after PYLARIFY’s potential year-end 2024 pass-through payment expiration.
- Updates on PNT2002 overall-survival data and regulatory plans, and the timing and outcome of the PNT2003 patent litigation and ANDA review.
- The value and risks of the Perspective investment and options, including further development, licensing and financing outcomes.
- Whether cash generation remains sufficient for operating needs, planned pipeline investment and $575.0 of convertible-note principal due in 2027, while maintaining credit-facility covenant compliance.
- Developments in Mo-99 supply, third-party manufacturing reliability and other supply-chain exposures.